Saturday's attack is the biggest on Saudi oil infrastructure since Saddam Hussein's invasion of Kuwait in 1990.Energyread more
Saudi Aramco is aiming to restore by Monday about a third of its crude output that was disrupted after drone attacks on two key oil facilities, The Wall Street Journal...Marketsread more
"Blaming Iran won't end disaster. Accepting our April '15 proposal to end war & begin talks may," Zarif said on Twitter.Energyread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
Apple's new iPhones can still send texts, download apps, and make video calls, but the company spends a lot of time and effort marketing its new phones as powerful photography...Technologyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
Some U.S. manufacturers say tariffs, if targeted, will help address longstanding unfair trade practices like intellectual property theft.Traderead more
Supporters of a $15 minimum wage ballot initiative in Florida argue the state's inflation-tied pay hikes have not gone far enough.2020 Electionsread more
Saudi Arabia shut down half its oil production Saturday after drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's Houthi rebels.Politicsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
The Food and Drug Administration has approved Xofluza, the first new antiviral flu treatment in nearly 20 years.
Genentech's Xofluza, baloxavir marboxil, is meant to treat acute uncomplicated influenza in patients 12 years and older who have had symptoms for no more than 48 hours. Genentech is a unit of Roche, which produces Tamiflu, a commonly used flu treatment.
The single-dose treatment will be available across the U.S. in the coming weeks, a Genentech spokesman told CNBC. It will cost $150 but may be available to some patients with commercial insurance for $30, he added.
"With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option," FDA Commissioner Dr. Scott Gottlieb said in a statement.
The FDA in June granted Xofluza priority review based on results of the Phase 3 CAPSTONE-1 study. Results from the trial, published in the New England Journal of Medicine, showed Xofluza reduced the amount of time a person was sick by a little more than a day.
"XOFLUZA is the first new flu medicine with a novel proposed mechanism of action approved in nearly 20 years, and we're excited to offer a convenient treatment option that reduces flu symptoms by more than a day with a single oral dose," Dr. Sandra Horning, chief medical officer and head of global product development at Genentech, said in a statement.
While the drug can treat the flu, the FDA in approving the drug reminds people that it is not a replacement for the flu vaccine. The CDC recommends getting vaccinated by the end of October.
— CNBC's Jodi Gralnick contributed to this report